Alphamab Oncology, a leading biopharmaceutical company in China, has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical study for its drug candidate, JSKN003. This study, identified as JSKN003-202, will focus on the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, collectively known as platinum-resistant ovarian cancer $(PROC)$. The study will be randomized, open-label, and multi-center. This advancement highlights Alphamab Oncology's proprietary protein engineering expertise and commitment to developing next-generation biological drug candidates. The company has not specified any collaboration with other organizations regarding this regulatory approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.